130 related articles for article (PubMed ID: 36606874)
21. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
22. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
[TBL] [Abstract][Full Text] [Related]
23. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
24. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
25. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
26. Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.
Matsuura K; Sakamaki K; Honda J; Sozu T
J Biopharm Stat; 2023 Sep; 33(5):639-652. PubMed ID: 36717962
[TBL] [Abstract][Full Text] [Related]
27. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Razaee ZS; Cook-Wiens G; Tighiouart M
Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
[TBL] [Abstract][Full Text] [Related]
28. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
29. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
30. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
Shi H; Cao J; Yuan Y; Lin R
Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
[TBL] [Abstract][Full Text] [Related]
31. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
32. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
33. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials.
Zhou Y; Zhao Y; Cicconetti G; Mu Y; Yuan Y; Wang L; Penugonda S; Salman Z
Pharm Stat; 2023 Mar; 22(2):300-311. PubMed ID: 36333972
[TBL] [Abstract][Full Text] [Related]
34. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
[TBL] [Abstract][Full Text] [Related]
35. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
36. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
37. Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes.
Jin H; Yin G
Pharm Stat; 2023; 22(5):773-783. PubMed ID: 37095681
[TBL] [Abstract][Full Text] [Related]
38. Comparison between continuous and discrete doses for model based designs in cancer dose finding.
Diniz MA; Tighiouart M; Rogatko A
PLoS One; 2019; 14(1):e0210139. PubMed ID: 30625194
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
Cunanan K; Koopmeiners JS
BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
[TBL] [Abstract][Full Text] [Related]
40. Nonparametric overdose control with late-onset toxicity in phase I clinical trials.
Lin R; Yin G
Biostatistics; 2017 Jan; 18(1):180-194. PubMed ID: 27549121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
